SineuGene Therapeutics Co., Ltd. Was founded in China, one of its stakeholders is Tsinghua University.
SineuGene Therapeutics, located in Changping District, Beijing, China, is a pharmaceutical company that dedicates to gene therapy for patients with neurodegenerative diseases. All three co-founders came from Tsinghua University or have served Tsinghua for 10 years. Therefore, all SineuGene original translational ideas and targets were conceived and discovered at Tsinghua, which makes Sineugene unique in the field.
SineuGene started the cooperation with PackGene（Guangzhou） to Screen the new AAV serotypes for Central Nervous System(CNS)
SineuGene was officially settled and officially operated in the ATLATL International Innovation Platform of Changping District.
Dr Peng Lin and Dr Guo Wei both joined SineuGene as full time employees and Co-founders
The Ceremony of the Science Advisory Committee of SineuGene was held successfully. During it, the Science Advisory Committee of SineuGene was founded and Prof. Jia Yichang was elected as chair of it. More than 20 famous scientists attend the ceremony and joined the committee to support SineuGene. One of them is Prof. Wang Yizheng, an Academician of the Chinese Academy of Sciences and a neurobiologist. Mr. Yang Renquan, a member of the Standing Committee of the Changping District Committee of Beijing/Deputy Mayor, attended this ceremony and give his congratulations.
Mr. Zhao Yan, Deputy Secretary of the Party Committee and CEO of Tsinghua Holdings Co., Ltd., visited SineuGene
Mr Chen Jining, Mayor of Beijing City, visited SineuGene
SineuGene started developing animal models of nervous system diseases with Cyagen.
Prof. Jia Yichang, co-founder of SineuGene, was invited to participate and give a talk about ALS in the 2nd Rare Diseases Forum for ALS, which theme is "Joining Hands to Unfreeze Love and Sharing Precious Times"?
Prof. Jia Yichang, Co-founder of SineuGene was interviewed by Deeptech on “the Global ALS Awareness Day” of 2022.
SineuGene was settled in Peking University Medical Innovation Valley
Dr. Jia Yichang, co-founder and chairman of the scientific committee of SineuGene, was hired as a tenured professor at Tsinghua University
SNUG01, the first pipeline of SineuGene, was officially started manufacturing by CDMO in PackGene
SineuGene was awarded as the Leading biotech company in life sciences and pharmacy fields in the 11th China Innovation and Entrepreneurship Competition of the Beijing Division.
SineuGene was awarded as the Leading biotech company in life sciences and pharmacy fields in the 11th China Innovation and Entrepreneurship Competition of the Beijing Division.
SG006 pipeline was officially launched, which may be the first Gene Therapy Project initiated and funded by a patient in China.
The formation of the core values of SineuGene.
SineuGene has obtained the qualification of a technology-based small and medium-sized enterprise (SMEs) through the review and approval process of being listed in a technology-based SMEs database.
Dr. Guo Weibo, co-founder and Chief Scientific Officer of SineuGene, was invited to participate in the ICNS 2022 2nd Central Nervous System Drug Deep Focus Forum, where he gave a special report entitled "AAV Gene Therapy Development for Neurological Disorders".
Prof. Jia Yichang and Dr. Peng Lin were invited to participate in the 2022 International Conference on Translational Brain Science and give a speech.
Researcher Xianying Zhang from the R&D Department of SineuGene has successfully published research results in CELL.
During the lockdown period of the COVID-19 in Beijing, the "Overcoming Difficulties" project team of SineuGene set up military beds in the conference room.
SineuGene was ed as one of the top 150 companies in the Enterprise Group for the 7th "Maker in China" competition.
The new 1,200-square-meter site (including a 400-square-meter AAV GMP-Like level workshop) has been put into use.
Researchers at Jia-Lab have discovered a new molecular mechanism for controlling mammalian vocalization through the transcription factor TCF7L2. The findings have important implications for understanding language evolution and neurological disorders such as autism. The research has been accepted for publication in the scientific journal Molecular Psychiatry.
The second meeting of the Scientific Advisory Committee was held, and the new 1200 square meter venue was officially launched.
Recognized as a National High-tech Enterprise.
The first ALS patient in China treated with SNUG01 AAV gene therapy completed one-year follow-up, showing stable disease progression.
SineuGene partnered with Mr. Cai Lei to establish a joint laboratory dedicated to advancing ALS drug research.
SineuGene completed a nearly RMB 100 million Pre-A financing round, led by Zhongguancun Capital with participation from Zhongbo Juli, Transfar Capital, and Sanmei Investment.
SineuGene was recognized among the “Top 10 Innovations in Neuropsychiatric Medicine 2024.”
The investigator-initiated trial (IIT) of SNUG01 at Peking University Third Hospital completed enrollment and reported positive clinical results.
Braving the Winter: SineuGene Hosts Themed Salon on Opportunities and Challenges in CNS Innovative Drug Development.
SNUG01 launched a multi-center investigator-initiated trial (IIT) at Peking University Third Hospital.
SNUG01 multi-center IIT was initiated at the Second Affiliated Hospital of Zhejiang University School of Medicine.
SineuGene Launches Hangzhou Subsidiary.
SNUG01 multi-center IIT was initiated at Hospital, Fujian Medical University.
patient@sineugene.com
Office Tel: +86-10-6973-5800
Recruitment：hr@sineugene.com
Finance & Business：contact@sineugene.com
Copyright ? 2025 神濟(jì)昌華（北京）生物科技有限公司 版權(quán)所有
Copyright ? 2025 神濟(jì)昌華（北京）生物科技有限公司 版權(quán)所有